

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 April 2012 (26.04.2012)

(10) International Publication Number  
**WO 2012/052463 A1**

(51) International Patent Classification:  
*A61K 31/198* (2006.01)   *A61P 3/04* (2006.01)  
*A61P 1/14* (2006.01)

(21) International Application Number:  
PCT/EP2011/068231

(22) International Filing Date:  
19 October 2011 (19.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10188399.9   21 October 2010 (21.10.2010)   EP

(71) Applicants (for all designated States except US):  
NESTEC S.A. [CH/CH]; Avenue Nestlé 55, CH-1800 Vevey (CH). INRA [FR/FR]; 147 Rue de l'Université, F-75338 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BREUILLE, Denis [FR/CH]; Chemin de la Granette 15, CH-1010 Lausanne (CH). PAPET, Isabelle [FR/FR]; 79 avenue du Limousin, F-63100 Clermont-Ferrand (FR). VIDAL, Karine [FR/CH]; Chemin de Bérée 56, CH-1010 Lausanne (CH).

(74) Agent: MARQUARDT, Ulf; Avenue Nestlé 55, CH-1800 Vevey (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))



**WO 2012/052463 A1**

(54) Title: CYSTEINE AND FOOD INTAKE

(57) Abstract: The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment and/or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population.

## Cysteine and food intake

The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a 5 nutritional composition enriched in cysteine for use in the treatment or prevention of malnutrition and disorders related thereto. Such a composition may in particular, but not exclusively, be useful for the elderly population.

Anorexia is the decreased sensation of appetite. Many possible 10 causes exist for a decreased appetite, some of which may indicate a serious clinical condition, or pose a significant risk. Oftentimes anorexia is a consequence of other illnesses. Under such circumstances malnutrition is a significant problem since it will delay the recovery process and may even prevent 15 a full recovery.

Anorexia is often present in the ageing population. Despite the increase in body fat and obesity that occurs with aging, there is a linear decrease in food intake over the life span. This may be explained by decreased physical activity and an 20 altered metabolism with aging. Ageing-associated anorexia may have substantial adverse effects. The age-associated physiologic reduction in appetite and food intake has been termed "the anorexia of aging". 'Physiological' anorexia and weight loss of ageing predispose to pathological weight loss 25 and malnutrition. This physiologic anorexia is caused for example by an altered hormonal and neurotransmitter regulation of food intake. Marked weight loss in the elderly drives morbidity and increased mortality, has a negative impact on the quality of life and contributes to frailty.

Today, anorexia is often treated by administration of a variety of medicaments, some of which may have unwanted side effects.

Consequently, there is a need in the art for a natural way to

5 treat and/or prevent malnutrition and disorders related thereto without unwanted side effects, in particular in the elderly. Ideally, this should be accomplished by a composition that is available to everyone, is liked by the consumers and can be used on a daily basis.

10 The present inventors have addressed this need.

Hence, it was the object of the present invention to improve the state of the art and to provide the art with a composition that achieves the object of the present invention.

The inventors were surprised to see that they could achieve

15 this object by the subject matter of the independent claim. The dependant claims further develop the idea of the present invention.

In particular the inventors have found that cysteine can be used, e.g. as part of a composition for enteral nutrition or a 20 food product, to maintain or improve food intake, for example in the elderly.

The inventors found that cysteine exhibits an anti-anorexic property, for example an anti ageing-associated anorexia property. Such effect was not observed with alanine-

25 supplemented diet (control diet). To the inventor's best knowledge, this is the first description of a beneficial effect of cysteine on food intake. Consequently, providing cysteine-rich diet or adding cysteine to a food product, for example in a quantity higher than the normal requirement would

allow counteracting the decrease in food consumption that occurs, e.g., in the elderly. There are also many health-related conditions are associated with anorexia, e.g. chemotherapy, infection, anorexia nervosa, or stress 5 conditions. Also here cysteine may be used to treat or prevent anorexia and related conditions. Hence, cysteine may also be used in clinical products to control food intake, for example.

Consequently, one embodiment of the present invention is a nutritional composition enriched in cysteine.

10 "Enriched" in cysteine means that cysteine was either added to a nutritional composition or that a food composition is treated in a way that its natural cysteine content per gram is increased. A composition is further considered "enriched" in cysteine if the composition contains cysteine in an amount 15 that exceeds the recommended daily intake (RDI). The recommended daily intake for cysteine for infants (0-12 months) is 45 mg/kg body weight; for children (1-17 years) 22 mg/kg body weight; and for adults ( $\geq$  18 years) 10 mg/kg body weight.

Cysteine may also be provided in the form of a cysteine 20 precursor selected from the group consisting of cysteine bound in a protein or a peptide hydrolysate or a peptide, for example gamma-glutamyl-cysteine, or another form of peptide, for example gamma-glutamyl-cysteine ester, mixed disulfides such as L-cysteine-glutathione cysteine prodrugs, N-acetyl-25 cysteine (free form, amide or ester forms), S-allyl-cysteine, S-methyl-cysteine, S-ethyl-cysteine, S-propyl-cysteine, TCA (thiazolidine carboxylic acid), OTC (L-2-Oxothiazolidine-4-carboxylate), bucillamine glutathione and glutathione esters (monomethyl, monoethyl, diethyl, isopropyl), glutathione 30 prodrugs, S-acetyl-glutathione, S-pheylacetate-glutathione, and S-hydroxy-methyl mercapto L-cysteine.

The composition of the present invention may be for use in the treatment and/or prevention of malnutrition and/or disorders related thereto.

5 The present invention also relates to the use of cysteine for the preparation of a composition to treat and/or prevent malnutrition and/or disorders related thereto.

The composition of the present invention may be additionally or alternatively for use in increasing food intake.

It may also be used for decreasing satiety and/or satiation.

10 Notably, the inventors found that the administration of the composition of the present invention allowed to significantly increase food intake. Hence, the composition of the present invention may also be used for increasing appetite.

15 The composition of the present invention allows increasing the willingness to eat as well as the total quantity of ingested food.

Hence, e.g., any disorder related to malnutrition may be treated by administration of the composition of the present invention. For example, the disorder related to malnutrition 20 may be selected from the group consisting of anorexia, anorexia nervosa, cachexia, inflammatory diseases associated with decreased food intake, or combinations thereof.

25 Low-grade inflammation appears to be an important parameter in the development of the homeosteny, for example associated with ageing. Age-associated low-grade inflammation may cause an increase mortality and morbidity, such as body weight loss. The present invention provides a new nutritional strategy to

counterbalance such negative effects of low-grade inflammation that may occur in the elderly, for example.

In one embodiment of the present invention, the composition may be to be administered to the elderly.

5 A subject is considered as "elderly" or "aged" if it has surpassed the first half of its average expected lifespan in its country of origin, preferably, if it has surpassed the first two thirds of the average expected lifespan in its country of origin, more preferably if it has surpassed the 10 first three quarters of the average expected lifespan in its country of origin, most preferred if it has surpassed the first four fifths of the average expected lifespan in its country of origin.

For example, the composition of the present invention may be 15 to be administered to a person at the age of at least 50 years, at least 60 years, at least 70 years or at least 80 years.

The composition of the present invention may also be to be administered to pets, for example aged pets.

The composition in accordance with the present invention may 20 be for use in the treatment or prevention of an age related decrease in food intake.

The compositions of the present invention will typically contain a protein fraction, a lipid fraction and a carbohydrate fraction.

25 The protein fraction may comprise at least 3.0 weight-%, at least 4 weight-%, at least 5 weight-%, at least 7 weight-% or at least 10 weight-% cysteine.

In case a subject suffers from an impaired functioning of the gastro-intestinal tract, it may be preferred if for example at least in part a protein source is used that is pre-hydrolyzed.

For the same reason it might be preferred if a lipid source 5 containing MCT (medium chain triglycerides) is used. MCTs have the advantage that they are easily absorbed by the body.

In the framework of the present invention cysteine may typically be administered in a daily dose in the range of about 0.03 to 0.15 g/kg body weight, for example 0.05 to 0.12 10 g/kg body weight.

In order to achieve such daily doses, the composition may contain cysteine in an amount of at least 2 g/kg dry weight, at least 4 g/kg dry weight, at least 6 g/kg dry weight, at least 8 g/kg dry weight, or at least 10 g/kg dry weight.

15 Cysteine from any source may be used in the framework of the present invention. Chemically pure cysteine has the advantage of being available in high purity and concentrations allowing a very precise dosing.

However, cysteine may also be provided from natural sources. 20 For example, cysteine may be provided from animal sources such as pork, sausage meat, chicken, turkey, duck, luncheon meat, eggs, milk, milk proteins, whey protein, ricotta, cottage cheese, and/or yogurt; and/or from vegan sources such as red peppers, garlic, onions, broccoli, Brussels sprouts, oats, 25 granola, and/or wheat germ.

These natural sources allow producing natural and effective food compositions without adding artificially produced compounds. It is also possible to meet specific dietary needs, such as for example for vegetarians or vegans.

The compositions of the present invention may have a caloric density of at least 0.5 kcal/g dry weight. Some people with an overall low food intake have problems to digest high caloric food. For such people low caloric formulations are preferred.

5      Otherwise, increasing food intake has a more pronounced effect if food with a higher caloric density is consumed. Hence, the compositions of the present invention may also have a caloric density of at least 0.8 kcal/g dry weight, at least 1.0 kcal/g dry weight, at least 1.5 kcal/g dry weight, or at least 2.0

10     kcal/g dry weight.

Typically, about 10 to 40 % of the calories of the composition may be from proteins. As in particularly elderly people often suffer from insufficient protein intake it may be preferred if about 20 to 40 % of the calories of the composition are from

15     proteins.

The composition may also comprise about 15 to 45 % of the calories of the composition from lipids, and/or about 20 to 70 % of the calories of the composition from carbohydrates.

The composition may be any kind of composition that is acceptable for human or animal consumption. For example, the composition may be selected from the group consisting of a food product, a pet food product, a drink, a pharmaceutical, a nutritional formula, a composition for clinical nutrition, a nutritional powder to be reconstituted by addition of water, a juice or milk, a nutraceutical, a food additive, a food supplement, a dairy product, or a gel.

Food additive or medicaments may be in the form of tablets, capsules, pastilles or a liquid for example.

The compositions may further contain protective hydrocolloids

30     (such as gums, proteins, modified starches), binders, film

forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc.), adsorbents, carriers, fillers, co-compounds, 5 dispersing agents, wetting agents, processing aids (solvents), flowing agents, taste masking agents, weighting agents, jellifying agents, gel forming agents, antioxidants and antimicrobials.

They may also contain conventional pharmaceutical additives 10 and adjuvants, excipients and diluents, including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, 15 colorants, wetting agents, fillers, and the like.

The composition may be to be administered orally, enterally or parenterally.

In general oral administration is preferred, since it can be easily done at home, and would consequently allow using the 20 subject matter of the present invention in a private atmosphere. Everybody could easily have access to and use the compositions of the present invention, optionally after consultation with medical personnel.

In hospitalized conditions, malnutrition and lack of appetite 25 is often a serious problem that may cause delays in the recovery process. For people not willing to or unable to consume food orally, enteral administration of the compositions of the present invention may be a preferred option, for example as tube feeding formulation.

If oral and/or enteral administration is not possible or not recommended, parenteral administration may be used. Hence, the composition of the present invention may also be in a form suitable for parenteral administration. Such compositions 5 often do not contain a carbohydrate source, for example.

The composition may be to be administered as a meal or in the framework of a meal.

The composition may also to be administered within one hour before or during a meal, for example. As such it may serve as 10 a functional appetizer, for example.

Those skilled in the art will understand that they can freely combine all features of the present invention described herein, without departing from the scope of the invention as disclosed. In particular, features described for the use of the present 15 invention may be applied to the compositions of the present invention and vice versa.

Further advantages and features of the present invention are apparent from the following Examples and Figures.

Figure 1 summarized the experimental design.

20 Figure 2 shows Kaplan-Meier survival curves of old rats fed with an alanine (A) and a cysteine (C) diet. Log-rank test = 0.054, P = 0.816.

Figure 3 shows the effect of cysteine supplementation on body weight. Two-way Anova for repeated measurements: Time (T): P < 25 0.0001, Diet (D): P = 0.915, TxD: P = 0.137. <sup>a to h</sup> time points not sharing a common letter are significantly different (Fisher's PLSD, P < 0.05).

Figure 4 shows the effect of cysteine supplementation on food intake. Two-way Anova for repeated measurements: Time (T): P <

0.0001, Diet (D):  $P = 0.0002$ , TxD:  $P < 0.0001$ . <sup>a to i</sup> time points not sharing a common letter are significantly different (Fisher's PLSD,  $P < 0.05$ ).

5 Examples:

A cohort of male Wistar rats born and breed in a non-specific-pathogen-free animal facility (Unité de Nutrition Comparée, INRA Theix) was used for the study. When rats were 18 month old they were weighted monthly to evaluate their body weight 10 change and blood was sampled in order to quantify inflammatory markers (acute phase proteins:  $\alpha$ 2-macroglobulin and fibrinogen). At the age of 21 months, rats were divided in two groups matched for body weight, body weight loss, and inflammatory status. Rats were fed with supplemented diets, 15 starting at the age of 21 months and for 14 weeks. The cysteine diet consisted in the commercial pelleted diet A04 (SAFE/UAR, Scientific Animal Food and Engineering, Villemoisson-sur-Orge, France) supplemented with 4.0 g of L-cysteine (Sigma) per kg, and the control diet was supplemented 20 with 2.9 g of L-alanine (Jerafrance) per kg (iso-nitrogenous diets). Experimental diets have been prepared at the Unité Préparation Aliments Expérimentaux, INRA Jouy-en-Josas. The amino acid composition of the commercial (non-supplemented) diet is presented in Table 1.

25 Table 1. Amino acid composition of the commercial diet (A04).

Amino acid	Content in protein (g/100g)	Content in the commercial diet (g/kg)
aspartic acid	7.5	12.22
threonine	3.5	5.70
serine	3.9	6.41
glutamate	20.3	33.15
proline	7.4	12.03
glycine	5.2	8.53
alanine	4.6	7.52

valine	4.3	6.98
cysteine	1.74	2.84
methionine	2.00	3.26
isoleucine	3.4	5.58
leucine	7.1	11.61
tyrosine	3.2	5.29
phenylalanine	4.4	7.18
lysine	4.5	7.29
histidine	2.3	3.69
arginine	5.6	9.17
Total	91.1	148.46

### 1- Mortality

Survival curves were generated by Kaplan-Meier method (Fig 2) and compared by the log-rank test in order to analyze the 5 effect of cysteine supplementation on mortality.

Cysteine supplementation did not change the mortality rate.

### 2- Body weight

Body weight (Fig 3) decreased with time and it became 10 significantly different from the initial value at 7 weeks of supplementation. The decrease accelerated at the end of the experiment since body weights of the two last weeks were different from each of the previous ones.

### 15 3- Food intake

Food intake (Fig 4) decreased with time and was lower for the alanine diet. The significant interaction between time and diet reveals that cysteine was able to blunt the decrease in food intake associated with aging. Indeed, food intake 20 significantly decreased by 0.96% per week in the alanine group

(significant linear regression  $r = 0.88$ ,  $P < 0.0001$ ) whereas it was unchanged in the cysteine group ( $r = 0.20$ ,  $P = 0.50$ ).

The consumption of the 4 g cysteine supplemented diet blunts the decrease in food intake that occurred when rats were about 5 22.5 months old suggesting that cysteine exhibit an anti ageing-associated anorexia property.

#### 4- Body weight, skeletal muscle and organ weights

As shown in Table 3, cysteine supplemented rats exhibited a 10 higher liver weight than control rats.

Table 3. Effect of cysteine supplementation on body, skeletal muscle and organ weights

<b>Parameter</b>	<b>Diet</b>	
	<b>Alanine</b> (n = 61)	<b>Cysteine</b> (n = 62)
Initial BW (g)	657 $\pm$ 10	661 $\pm$ 10
Final BW (g)	595 $\pm$ 13	613 $\pm$ 12
BW change (%/13 wk)	- 7.03 $\pm$ 1.60	- 6.27 $\pm$ 1.18
Gastrocnemius (g)	2.51 $\pm$ 0.04	2.51 $\pm$ 0.04
Tibialis (mg)	888 $\pm$ 16	889 $\pm$ 18
EDL (mg)	222 $\pm$ 4	228 $\pm$ 4
Soleus (mg)	177 $\pm$ 3	178 $\pm$ 4
Liver (g)	18.4 $\pm$ 0.5	20.0 $\pm$ 0.4
Small intestine (g)	11.4 $\pm$ 0.3	12.0 $\pm$ 0.2
Colon (g)	2.68 $\pm$ 0.06	2.76 $\pm$ 0.07
Kidneys (g)	4.32 $\pm$ 0.19	4.31 $\pm$ 0.17

BW: body weight.

## Claims:

1. Cysteine for use in the treatment and/or prevention of malnutrition and/or disorders related thereto.
2. Cysteine for use in accordance with claim 1, wherein the cysteine is provided in the form of a cysteine precursor selected from the group consisting of cysteine bound in a protein or a peptide hydrolysate or a peptide, for example gamma-glutamyl-cysteine, or another form of peptide, for example gamma-glutamyl-cysteine ester, mixed disulfides such as L-cysteine-glutathione cysteine prodrugs, N-acetyl-cysteine (free form, amide or ester forms), S-allyl-cysteine, S-methyl-cysteine, S-ethyl-cysteine, S-propyl-cysteine, TCA (thiazolidine carboxylic acid), OTC (L-2-Oxothiazolidine-4-carboxylate), and S-hydroxy-methyl mercapto L-cysteine.
3. Cysteine for use in accordance with one of the preceding claims for use in increasing food intake, and/or for decreasing satiety and/or satiation.
4. Cysteine for use in accordance with one of the preceding claims for increasing appetite.
5. Cysteine for use in accordance with claim 1, wherein the disorder related to malnutrition is selected from the group consisting of anorexia, anorexia nervosa, cachexia, inflammatory diseases associated with decreased food intake, or combinations thereof.
6. Cysteine for use in accordance with one of the preceding claims to be administered to an elderly subject.

7. Cysteine for use in accordance with one of the preceding claims to treat and/or prevent an age related decrease in food intake.
- 5 8. Cysteine for use in accordance with one of the preceding claims, wherein the cysteine is provided in the form of a nutritional composition.
- 10 9. Cysteine for use in accordance with one of the preceding claims, wherein the nutritional composition contains a protein fraction comprising at least 3.0 weight-% cysteine, and/or wherein the cysteine is administered in a daily dose in the range of about 0.03 to 0.15 g/kg body weight.
- 15 10. Cysteine for use in accordance with one of the preceding claims, wherein the nutritional composition is to be administered orally, enterally or parenterally, and wherein the nutritional composition is to be administered within one hour before a meal, during a meal, or as replacement of a meal.
- 20 11. A nutritional composition comprising at least 3.0 weight-% cysteine, preferably at least 4.0 weight-% cysteine, more preferably at least 5.0 weight-% cysteine.
- 25 12. The nutritional composition in accordance with claim 11, wherein the nutritional composition has a caloric density of at least 0.5 kcal/g.
13. The nutritional composition in accordance with claim 11 or 12, wherein the nutritional composition comprises about 10 to 40 % of the calories of the nutritional composition from proteins.

14. The nutritional composition in accordance with one of the claims 11 to 13, wherein the nutritional composition comprises about 15 to 45 % of the calories of the nutritional composition from lipids, and/or about 20 to 70 % of the calories of the nutritional composition from carbohydrates.

5

15. The nutritional composition in accordance with one of the claims 11 to 14, wherein the nutritional composition is selected from the group consisting of a food product, a pet food product, a drink, a pharmaceutical, a nutritional formula, a composition for clinical nutrition, a nutritional powder to be reconstituted by addition of water, a juice or milk, a nutraceutical, a food additive, a food supplement, a dairy product, or a gel.

10

15

Figure 1:




Figure 2 :




Figure 3:





Figure 4 :



# INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2011/068231

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61K31/198 A61P1/14 A61P3/04  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, FSTA

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 627 152 A (KENYHERCZ THOMAS M [US] ET AL) 6 May 1997 (1997-05-06) claims 1-7; examples 1-3 -----	1-15
X	US 2007/286909 A1 (SMITH DANIEL S [US] ET AL) 13 December 2007 (2007-12-13) claims 18,19,29,35,36; tables 2-3 -----	1-15
X	JP 5 294833 A (TAKEDA CHEMICAL INDUSTRIES LTD) 9 November 1993 (1993-11-09) abstract -----	1,2,4,8, 15
X	JP 62 286923 A (SHINODA TAKAO) 12 December 1987 (1987-12-12) abstract ----- -----	1-4,15 -/-

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 November 2011	30/11/2011
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Estañol, Inma

## INTERNATIONAL SEARCH REPORT

International application No PCT/EP2011/068231
---

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2009/324518 A1 (KORTH RUTH-MARIA [DE]) 31 December 2009 (2009-12-31) paragraph [0048] - paragraph [0053]; claims 3-15 -----	1-3,5
X	US 2005/153019 A1 (FUCHS EILEEN C [US] ET AL) 14 July 2005 (2005-07-14) paragraph [0059] - paragraph [0063]; examples 1-7; table 1 -----	1-15
X	US 2005/215640 A1 (BAXTER JEFFREY H [US] ET AL) 29 September 2005 (2005-09-29) example 5 -----	1-15
X	WO 02/15720 A2 (NESTLE SA [CH]; AGRONOMIQUE INST NAT RECH [FR]) 28 February 2002 (2002-02-28) the whole document -----	1,2,5,6, 11-15
X	US 4 665 082 A (MEISTER ALTON [US] ET AL) 12 May 1987 (1987-05-12) the whole document -----	1-3,5-7, 15
X	MBODJI K ET AL: "P233 EFFECT OF A NEW ORAL SUPPLEMENT ENRICHED IN CYSTEINE ON NUTRITIONAL STATUS OF STRESSED RATS", CLINICAL NUTRITION SUPPLEMENTS, ELSEVIER, vol. 4, no. 2, 1 January 2009 (2009-01-01) , page 123, XP026747305, ISSN: 1744-1161, DOI: DOI:10.1016/S1744-1161(09)70283-2 [retrieved on 2009-01-01] the whole document -----	1-15
X	RO 119 122 B1 (DOBRESCU DUMITRU [RO]; DOBRESCU LILIANA [RO]) 30 April 2004 (2004-04-30) abstract -----	1,2,5,6, 15

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2011/068231

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5627152	A	06-05-1997	NONE		
US 2007286909	A1	13-12-2007	US 2007286909 A1		13-12-2007
			US 2011081329 A1		07-04-2011
JP 5294833	A	09-11-1993	NONE		
JP 62286923	A	12-12-1987	NONE		
US 2009324518	A1	31-12-2009	DE 102005062417 A1		23-08-2007
			DE 112006003777 A5		27-11-2008
			EP 1965791 A1		10-09-2008
			US 2009324518 A1		31-12-2009
			WO 2007073727 A1		05-07-2007
US 2005153019	A1	14-07-2005	US 2002044988 A1		18-04-2002
			US 2005153019 A1		14-07-2005
US 2005215640	A1	29-09-2005	AU 2005235133 A1		03-11-2005
			BR PI0509017 A		07-08-2007
			CA 2560042 A1		03-11-2005
			CN 101212961 A		02-07-2008
			EC SP066873 A		24-11-2006
			EP 1727534 A2		06-12-2006
			EP 2301529 A1		30-03-2011
			JP 2007530542 A		01-11-2007
			KR 20060134181 A		27-12-2006
			US 2005215640 A1		29-09-2005
			US 2007093553 A1		26-04-2007
			WO 2005102301 A2		03-11-2005
WO 0215720	A2	28-02-2002	AT 313273 T		15-01-2006
			AU 9177701 A		04-03-2002
			AU 9548801 A		04-03-2002
			BR 0113367 A		29-07-2003
			BR 0113390 A		29-07-2003
			CA 2418285 A1		28-02-2002
			CA 2419026 A1		28-02-2002
			CN 1469712 A		21-01-2004
			CN 1471363 A		28-01-2004
			DE 60116112 T2		03-08-2006
			DE 60126104 T2		15-11-2007
			EP 1313376 A2		28-05-2003
			EP 1313378 A2		28-05-2003
			ES 2254496 T3		16-06-2006
			ES 2278781 T3		16-08-2007
			HU 0301475 A2		28-08-2003
			HU 0301586 A2		28-08-2003
			JP 2004506436 A		04-03-2004
			JP 2004506437 A		04-03-2004
			MX PA03001598 A		01-11-2004
			MX PA03001600 A		04-06-2003
			PL 365934 A1		10-01-2005
			PL 365936 A1		24-01-2005
			RU 2277354 C2		10-06-2006
			RU 2277355 C2		10-06-2006
			WO 0215719 A2		28-02-2002
			WO 0215720 A2		28-02-2002

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No

PCT/EP2011/068231

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
<hr/>			
US 4665082	A 12-05-1987	NONE	
<hr/>			
RO 119122	B1 30-04-2004	NONE	
<hr/>			